The first experimental Ebola vaccines from the World Health Organization have arrived in the Democratic Republic of Congo, and the country will begin inoculations this weekend. Meanwhile, Public Health Minister Oly Ilunga Kalenga said an Ebola case had been found in Mbandaka, a city of about 1 million.
The Cherokee Nation began a hepatitis C prevention program three years ago with the goal of screening 80,000 of its 350,000 members, and over 50% of the target group has been screened, while 90% of people with detected cases who have received care have responded to treatment. John Ward of the CDC said the program is "a trailblazing project for the entire country."
Roche will present data from its late-stage HAVEN 3 and HAVEN 4 clinical trials evaluating its candidate Hemlibra, or emicizumab, on May 21 at the World Federation of Hemophilia 2018 World Congress in Scotland. The data include positive results showing the efficacy of Hemlibra in hemophilia A patients without factor VIII inhibitors dosed once weekly or every other week in the HAVEN 3 study and of doses given every four weeks for hemophilia A patients with or without factor VIII inhibitors in the HAVEN 4 trial.
The FDA has given final approval for Eagle Pharmaceuticals' ready-to-dilute bendamustine hydrochloride solution in a 500ml admixture, an injection that requires no reconstitution, to treat patients with chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma.
Dosing has begun in a Phase I/II clinical trial of BioMarin Pharmaceutical's gene therapy candidate valoctocogene roxaparvovec for patients with severe hemophilia A with pre-existing adeno-associated virus type 5 antibodies. The trial is expected to run through June 2024.
A study of 1,959 young, nulliparous, nonpregnant women in Burkina Faso, where malaria is hyperendemic, found that weekly administration of iron supplements was not associated with improved iron status, decreased anemia or increased risk of malaria, and researchers suggested re-evaluating World Health Organization guidance on supplementation. The findings were published in the Journal of Infectious Diseases.
LogicBio Therapeutics will present information on its gene editing technology for hemophilia B and methylmalonic acidemia at the American Society of Gene & Cell Therapy annual meeting. The company will discuss data from a study that tested a single injection in mouse models of hemophilia B.
A screening method for preeclampsia that includes measurement of biomarkers in addition to the mother's risk factors outperforms a standard method, which relies on medical history and maternal characteristics. "It is now time to revise the professional guidelines and to move away from using a checklist-based method for screening," said study co-author Liona Poon.
CareDx and Illumina have reached a licensing deal on Illumina's next-generation sequencing transplant clinical application products. CareDx will be the exclusive global distributor of Illumina's TruSight HLA v1 and v2 product lines and associated software, which it plans to use for diagnostic testing for bone marrow and solid organ transplantation.